Cingulate獲納入富時羅素3000E指數 8-K公告里程碑

EX-99.1
3
ex99-1.htm
EX-99.1

 

 

Exhibit 99.1

 

Cingulate
Inc. (NASDAQ: CING) Added to Russell 3000E®

CEO
Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors

 

KANSAS
CITY, Kan., July 2, 2026 — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed
Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products,
today announced it has been added to the Russell 3000E® Index.

 

“Being
added to the Russell 3000E® Index is a significant achievement that underscores Cingulate’s continued evolution as a public
company,” said Cingulate CEO Shane J. Schaffer. “We believe this inclusion will enhance our visibility with institutional
investors, expand market awareness, and further position the company for long-term growth. As we advance CTx-1301, our lead ADHD product
candidate, and continue developing our Precision Timed Release™ (PTR™) platform, we remain committed to executing our strategy
while creating lasting value for patients and shareholders alike.”

 

Russell
US Indexes serve as leading benchmarks for institutional investors. The modular index construction allows investors to track current
and historical market performance by specific market segment or investment style. The Russell 3000E Index measures the performance of
approximately 4,000 of the largest investable US equities. All Russell Indexes are fully reconstituted each June to ensure they accurately
reflect their targeted market segments and will be subject to semi-annual reconstitution beginning in December 2026.

 

About
Attention Deficit/Hyperactivity Disorder (ADHD)

 

ADHD
is a chronic neurobiological and developmental disorder that affects millions of children and often continues into adulthood. The estimated
market size of the US ADHD market is approximately 100 million annual prescriptions. The condition is marked by an ongoing pattern of
inattention and/or hyperactivity-impulsivity that interferes with functioning or development. In the U.S., over 20 million patients have
been diagnosed with ADHD. Among this group, 12 million are adults and over 8 million are under the age of 17. According to the CDC,
just 53.6 percent of all children and teens with ADHD reported they were actively treating their symptoms with medication in 2022, with
65-90 percent demonstrating clinical ADHD symptoms that persist into adulthood. Current market trends demonstrate that adult ADHD prevalence
is larger and growing faster than the child and adolescent segments combined.

 

About
CTx-1301

 

CTx-1301
(dexmethylphenidate HCl) is a once-daily, multi-core tablet utilizing Cingulate’s proprietary Precision Timed Release™ (PTR™)
platform to deliver three precisely timed releases of active medication across the day. This design aims to provide rapid onset of effect
and entire active-day duration. CTx-1301 is being evaluated for the treatment of ADHD under the FDA’s 505(b)(2) pathway.

 

  

  

 

 

About
Precision Timed Release™ (PTR™) Platform Technology

 

Cingulate
is developing ADHD and anxiety disorder product candidates capable of achieving true once-daily dosing using Cingulate’s innovative
PTR drug delivery platform technology. It incorporates a proprietary Erosion Barrier Layer (EBL) providing control of drug release at
precise, pre-defined times with no release of drug prior to the intended release. The EBL technology is enrobed around a drug-containing
core to give a tablet-in-tablet dose form. It is designed to erode at a controlled rate until eventually the drug is released from the
core tablet. The EBL formulation, Oralogik™, is licensed from BDD Pharma. Cingulate intends to utilize its PTR technology to expand
and augment its clinical-stage pipeline by identifying and developing additional product candidates in other therapeutic areas in addition
to Anxiety and ADHD where one or more active pharmaceutical ingredients need to be delivered several times a day at specific, predefined
time intervals and released in a manner that would offer significant improvement over existing therapies. To see Cingulate’s PTR
Platform, click here.

 

About
Cingulate Inc.

 

Cingulate
Inc. (NASDAQ: CING), is a biopharmaceutical company utilizing its proprietary PTR drug delivery platform technology to build and advance
a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed
conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment
of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future
product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information, visit Cingulate.com.

 

Forward-Looking
Statements 

 

This
press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than
statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including
statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical
studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities
and other statements that are predictive in nature. Specifically, these statements include, but are not limited to, the anticipated benefits
of the Company’s inclusion in the Russell 3000E® Index, including expectations regarding increased visibility among institutional
investors, expanded market awareness, and long-term growth opportunities . These statements are generally identified by the use of such
words as “may,” “could,” “should,” “would,” “believe,” “anticipate,”
“forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,”
“outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. Readers
are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results
may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings
with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10-K
filed with the SEC on March 18, 2026 and our other filings with the SEC. All forward-looking statements speak only as of the date on
which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except to the extent required by law.

 

Investor
& Media Relations:

 

Thomas
Dalton

Vice
President, Corporate and Government Relations, Cingulate

[email protected]

(480)
529-5434